

## DAFTAR PUSTAKA

1. Achmad D, Panigoro SS, Haryono SJ, Purwanto H, Sudarsa IW, Harahap WA., *et al.* (2023). Panduan Tatalaksana Kanker Tiroid PERABOI 2023. Edisi Pertama. Jakarta: PERABOI
2. Ammar A, Patel AJ, Reddy S. Cancer of the Endocrine. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, editors. (2020). *Abeloff's Clinical Oncology*. Sixth. Philadelphia: Elsevier Inc, p. 1074–80.
3. Bradly DP, Reddy V, Prinz RA, Gattuso P. (2009). Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. *Surgery*. Dec;146(6):1099–104.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, *et al.* (2009). Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*. 19 (11):1167–214.
5. De Carvalho AY, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP., *et al.* (2021) Predictive factors for recurrence of papillary thyroid carcinoma: Analysis of 4,085 patients. *Acta Otorhinolaryngologica Italica*. 2021;41(3):236–42.
6. Dedivitis RA, de Matos LL, Guimarães AV, de Castro MAF, Petrarolha SP. (2020) Neck recurrence in papillary thyroid carcinoma. *Rev Col Bras Cir*. 47:1–5.
7. Fraker DL. (1995). Radiation Exposure and other Factors that Predispose to Human Thyroid Neoplasia. *Surgical Clinics of North America*. 75(3):365–75.
8. Grogan RH, Kaplan SP, Cao H, Weiss RE, DeGroot LJ, Simon CA, *et al.* (2013). A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. *Surgery*. 154(6):1436–47.
9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, *et al.* (2015) American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 26(1):1–133.

10. Ito Y, Fukushima M, Kihara M, Takamura Y, Kobayashi K, Miya A, *et al.*, (2012) Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. *Endocr J.* 59 (6):457-64.
11. Kang IK, Kim K, Park J, Bae JS, Kim JS. (2022). Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma. *Cancers* (Basel). 14(15):3677.
12. Kang IK, Park J, Bae JS, Kim JS, Kim K. (2023). Lymph Node Ratio Predicts Recurrence in Patients with Papillary Thyroid Carcinoma with Low Lymph Node Yield. *Cancers* (Basel). 15(11):1–11.
13. Kotwal A, Davidge-Pitts C, Thompson GB. Thyroid tumors. In: Devita VT, Lawrence TS, Rosenberg SA, editors. (2019). *Cancer: Principles and Practice of Oncology*. 11th ed. Philadelphia: Wolters Kluwer Health. p. 2358–70.
14. Lang BH-H, Chow S-M, Lo C-Y, Law SCK, Lam K-Y. (2007). Staging Systems for Papillary Thyroid Carcinoma. *Ann Surg.* 246(1):114–21.
15. Limaïem F, Rehman A, Anastasopoulou C, *et al.* (2023). Papillary Thyroid Carcinoma. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing
16. Ma T, Cui J, Shi P, Liang M, Song W, Zhang X, *et al.* (2023). Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma. *Front Endocrinol* (Lausanne). 14(9):1–10.
17. Maggiore R, Perticone F, Mari G, Pasquali R, Bosi E, Scavini M, *et al.* (2021). Impact of the 8th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45–54 Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report. *Int J Endocrinol.* page 1–5.
18. Mansour J, Sagiv D, Alon E, Talmi Y. (2018). Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma. *J Laryngol Otol.* 132(1):8–13.
19. Megwalu UC, Moon PK. (2022). Thyroid cancer incidence and mortality trends in the United States: 2000-2018. *Thyroid.* 32(5):560–70.
20. Moore KL, Dalley AF, Agur AMR. (2018) Clinically Oriented Anatomy. 8th ed. Philadelphia: *Wolters Kluwer Health*. 2293–2297 p.

21. Nwogu, C.E.; Groman, A.; Fahey, D.; Yendamuri, S.; Dexter, E.; Demmy, T.L.; Miller, A.; Reid, M. (2012). Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. *Ann. Thorac. Surg.* 93, 1614–1619
22. Ortiz S., Rodriguez J.M., Soria T., Perez-Flores D., Pinero A., Moreno J., Parrilla P. (2001). Extrathyroid spread in papillary carcinoma of the thyroid: Clinicopathological and prognostic study. *Otolaryngol Head Neck Surg.* 124:261–265.
23. Park YM, Wang S, Lee J, Shin DH, Kim I, Son S, *et al.* (2016) Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. *Head Neck.* 38(S1):1391.
24. Parvathareddy SK, Siraj AK, Qadri Z, Ahmed SO, Devera F, Al-Sobhi S, *et al.* (2022). Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma. *Endocr Connect.* 11(2).
25. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. (2002). Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. *Surgery.* 131(3):249–56.
26. Randle RW, Pitt SC. (2021). The Role of Node Dissection for Thyroid Cancer. *Adv Surg;* 55:131–45.
27. Schneider DF, Mazeh H, Chen H, Sippel RS. (2013). Lymph Node Ratio Predicts Recurrence in Papillary Thyroid Cancer. *Oncologist.* 18(2):157–62.
28. Shokoohi A, Berthelet E, Gill S, Prisman E, Sexsmith G, Tran E, *et al.* (2020). Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience. *Cureus.* 12(2).
29. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL. (2004). Surgeon-Performed Ultrasound in the Management of Thyroid Malignancy. *Am Surg.* 28;70(7):576–82.
30. Surveillance, Epidemiology, and End Results Program. Cancer Stats Fact: Thyroid Cancer [Internet]. Maryland (US): SEER; 2023 [cited 2023 Jan 05]. Available from: <https://seer.cancer.gov/statfacts/html/thyro.html>

31. Su H.K, Wenig B.M, Haser G.C, Rowe M.E, Asa S.L, Baloch Z, Du E, Faquin W.C, Fellegara G, Giordano T, *et al.*, (2016). Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. *Thyroid*. 26:512–517.
32. Takami H, Ito Y, Okamoto T, Yoshida A. (2011). Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. *World J Surg*. 35(1):111–121
33. Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A, *et al.* (2004). Preoperative Ultrasonographic Examination for Lymph Node Metastasis: Usefulness when Designing Lymph Node Dissection for Papillary Microcarcinoma of the Thyroid. *World J Surg*. 28(5):498–501.
34. Tuttle RM, Morris LF, Haugen BR, Shah JP. (2018). Thyroid - Differentiated and Anaplastic Carcinoma. In: AJCC Cancer Staging Manual. Berlin, Heidelberg: *Springer Berlin Heidelberg*. p. 884–5.
35. US Department of Health and Human Services. (2023). Cancer stat facts: Thyroid cancer.
36. Wada N, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M, *et al.* (2007). Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. *Langenbecks Arch Surg*. 392(4):417–22.
37. Zarebczan B, Chen H. (2010). Multi-targetted approach in the treatment of thyroid cancer. *Minerva Chir*. 65:59–69.
38. Arroyo N, Bell KJL, Hsiao V, Fernandes-Taylor S, Alagoz O, Zhang Y, *et al.* (2022). Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies. *J Clin Endocrinol Metab*. 107(10):2945–52.
39. Kim TH, Kim YN, Kim HI, Park SY, Choe J-H, Kim J-H, *et al.* (2017). Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. *Oral Oncol*. 71:81–6.

40. Mao J, Zhang Q, Zhang H, Zheng K, Wang R, Wang G. (2020). Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)* [Internet]. 15;11.
41. Zhu J, Huang R, Yu P, Ren H, Su X. (2022). Male Gender Is Associated with Lymph Node Metastasis but Not with Recurrence in Papillary Thyroid Carcinoma. Casella C, editor. *Int J Endocrinol*. 28;1–9.
42. Chen L, Wu Y, Lee C, Chen H, Loh E, Tam K. (2018). Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. *World J Surg*. 27;42(9):2846–57.
43. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, *et al.* (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 26(1):1–133.
44. Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V. (2016). Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. *Cancer*. 122(9):1388–97.
45. Yu ST, Ge JN, Sun BH, Wei ZG, Xiao ZZ, Zhang ZC, *et al.* (2021). Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study. *Oral Oncol*. 123(1838):105567.
46. Heaton CM, Chang JL, Orloff LA. (2016). Prognostic Implications of Lymph Node Yield in Central and Lateral Neck Dissections for Well-Differentiated Papillary Thyroid Carcinoma. *Thyroid*. 26(3):434–40.
47. Noel JE, Orloff LA. (2020). Recognizing Persistent Disease in Well-Differentiated Thyroid Cancer and Association with Lymph Node Yield and Ratio. *Otolaryngol - Head Neck Surg (United States)*. 162(1):50–5.

48. Beal SH, Chen SL, Schneider PD, Martinez SR. (2010). An evaluation of lymph node yield and lymph node ratio in well- differentiated thyroid carcinoma. *Am. Surg.* 76, 28–32.
49. Vas Nunes J.H, Clark JR, Gao K, Chua E, Campbell P, Niles N, Gargya A, Elliott MS. (2013). Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. *Thyroid*, 23, 811–816.
50. Jeon, M.J.; Yoon, J.H.; Han, J.M.; Yim, J.H.; Hong, S.J.; Song, D.E.; Ryu, J.S.; Kim, T.Y.; Shong, Y.K.; Kim, W.B. (2013). The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. *Eur. J. Endocrinol.* 168, 219–225.
51. Nahm FS. (2022). Receiver operating characteristic curve: overview and practical use for clinicians. *Korean J Anesthesiol.* 75(1):25–36.